Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
Over 19 years of experience in R&D
Learn more
01 Drug Discovery
Chemistry Research

Fee For Service(FFS)

Full Time Equivalent(FTE)

Medicinal Chemistry

Synthetic Chemistry

Analytical Chemistry

Biology Research

Structural Biology

Cell Biology

Computational Biology & Molecular Modeling

Enzymology & Molecular Interactions

Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates
APIs

Route Selection

Production Process Optimization

Clinical Sample Production

Impurity Traceability & Control

Generic Drug Process Study & Filing

Innovative Drug Process Study & Filing

Pharmaceutical preparation

Preformulation Study

Formulation Technology Research

Preparation Quality Research

Laboratory-scale Preparation Testing

Pilot-scale Preparation Testing

GMP-based Clinical Sample Production & Packaging

Formulation Stability Study

Consistency Evaluation

Analytical Method Development and Quality Control
CMC Filings
03 Preclinical Research
Pharmacology & Pharmacodynamics

Tumor Models

Digestive System Disease Models

Endocrine & Metabolic Disease Models

Inflammatory & Immune Diseases Models

Neural System Disease Models

Other Disease Models

Drug Safety Evaluation

Pharmacology & Toxicology Study

Safety Pharmacology

Histopathological Study

Clinicopathological Study

Drug Safety Evaluation Basic Information

Toxicokinetics

Pharmacokinetics

In Vitro Pharmacokinetic Assays

In Vivo Pharmacokinetic Assays

Bioanalysis

Macromolecular Drugs Bioanalysis

Micromolecular Drugs Bioanalysis

IND Filings
01 One-stop Integrated Services
Pharmaceutical Research Platform
Drug Discovery Plarform
One-stop API Process R&D Department
Translational Medicine Platform
Pharmaceutical Research CDMO Service Platform
Chemical Drug Development
Medicilon's CDMO Service Platform
Preclinical Research Services
02 Key Technical Services for Drug R&D
Process Department Solid Form Screening Platform
SEND Format Conversion Platform
Flow Cytometry Technology Platform
Safety Assessment Lab of Process Chemistry
Drug Forming Research Platform
Metabolite Identification (MetID) Service Platform
Cytokine and Biomarker Detection Platform
03 Innovative Drug Services
Nucleic Acid Drug R&D Platform
Non-clinical Research for Cellular Immunotherapies
mRNA Vaccine Bioanalysis Platform
PROTAC Drug Discovery Research Platform
ADC R&D Service Platform
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Drug Efficacy Evaluation System
Pharmacodynamic Evaluation Model Platform for Inflammatory and Immune Diseases
IO Pharmacodynamic Model Evaluation Platform
05 Advanced Preparation R&D
Skin Topical Preparation R&D
Ophthalmic drug R&D platform
Inhalation drug R&D platform
06 Drug Analysis
07 Public Services
CLIENT CENTER
Intellectual Property Protection
Downloads
Partnerships
Newsletters
U.S.

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880

UK

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954

Email: marketing@medicilon.com

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

News
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
2023-03-20Market Events
Join Medicilon at SAPA-GP 2023 Annual Conference

Date: 3.31-4.1 2023

Location: King of Prussia, Pennsylvania

Learn more
2023-03-14Market Events
Join Medicilon at BioTrinity 2023: Catalysing Growth in the Life Sciences Industry

Date: April 25-26, 2023

Location: Etc. venues 155 Bishopsgate, London

Learn more
INVESTORS
Stock Information
Investment Contact
Medicilon 688202
RMB

As of Beijing time The data is from a third-party organization and is only for reference.

For actual information, please refer to：www.eastmoney.com

CAREERS
Talent Development
Employee Activities
Campus Recruitment
Social Recruitment
Campus Recruitment
Campus Recruitment
Social Recruitment
Social Recruitment
Close

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3

Shanghai Public Network Security File No. 31011502018888 | Website Map

© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888|Website Map
关闭
CN
Contact Us
Close Button
Message
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events
Medicilon Events Featured Stories Market Events Videos A.C.E.
HomenewsMedicilon Events

Medicilon Events

Hot information：
Two Innovative Service Platforms of Medicilon were Selected as Shanghai International Service Trade Demonstration project| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon| Medicilon FTE services & FFS services - flexible and efficient cooperation model
Dec 22,2022
Medicilon wish you a merry christmas
Christmas is coming up! Wishing you all the Hope, Wonder, and Joy! Have a delicious time!
More
Medicilon wish you a merry christmas
Dec 09,2022
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Medicilon Antibody Development Technical Service is here to help you develop new drugs with high cost performance, high efficiency and high quality.
More
Holiday Promotion: Medicilon Antibody Development Technology Service with Discount Price
Dec 09,2022
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
On December 4th, with the completion of the last concrete pouring, the expansion project of the drug research and development laboratory of Shanghai Medicilon Inc has been completed. This marks the further strengthening of Medicilon's one-stop biopharmacetical preclinical R&D service platform capabilities.
More
Congratulation to the Expansion of Medicilon Drug Research and Development Laboratory
Nov 22,2022
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
​Recently, Shanghai Medicilon Inc. (Medicilon) signed a strategic collaboration agreement with Infinite Intelligence Pharma (IIP).
More
Medicilon and Infinite Intelligence Pharma Reached a Strategic Collaboration
Nov 22,2022
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
On November 10, 2022, the Listed Companies Association of Shanghai held the 4th member meeting of the association and the 1st meeting of council of the association through the online platform of East Money information. The meeting was presided over by Yuan Yi, Secretary of the Association, and supervised by the Shanghai Oriental Notary Public Office.
More
Medicilon was Elected as the Director Unit of The Listed Companies Association of Shanghai
Nov 18,2022
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Medicilon offer a full range of chemistry Research services covering all phases of your project requirements, and clients can work with us under either the FFS (project-based payment) or FTE (full-time equivalent service) models.
More
Medicilon FTE services & FFS services - flexible and efficient cooperation model
Nov 08,2022
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
On August 29, 2022, Beijing Peptide Biomedical Technology Co., Ltd. (Bejing Peptide) ZT002 injection was approved by the Australian Human Research Ethics Committee for Phase I clinical trials.
More
Medicilon assists Beijing Peptide's clinical application of semaglutide injection of semaglutide was accepted by CDE; ZT002 was promoted in China, US and Australia Filing
Nov 08,2022
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Recently, Shanghai Medicilon Inc. (Medicilon) appointed Dr. Renzong Xie as the Vice President of Toxicology Research Department.
More
Medicilon Appoints Dr. Renzong Xie DABT as Vice President of Toxicology Research
Oct 28,2022
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
On October 19, AnDiCon Bio (AnDiCon) officially launched the phase II/III clinical study of ADC189 tablets, a new class 1 anti-influenza drug. The drug is expected to become the first class 1 innovative anti-influenza drug independently developed and approved for marketing in China.
More
Assisting the development of the Chinese new anti-influenza drug ADC189 preparation, Medicilon and AnDiCon Bio reached a collaboration
Oct 21,2022
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Shanghai Medicilon Inc. was awarded the honorary title of "Top 30 Listed Companies on the Science and Technology Innovation Board".
More
Medicilon was awarded "Top 30 Listed Companies on the Science and Technology Innovation Board of China's Listed Companies"
Oct 19,2022
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Recently, Shanghai Medicilon Inc. (hereinafter referred to as "Medicilon") appointed Dr. Rui Zhang as Senior Vice President of CMC.
More
Medicilon appointed Dr. Rui Zhang as Senior VP of CMC
Sep 29,2022
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Recently, Ringene Biopharma, an innovative drug R&D company focusing on the development of drugs targeting RTK-RAS-MAPK signaling pathway, independently developed a new class of anti-tumor drugs, the irreversible pan-FGFR inhibitor RG002, which was approved clinical. The indications are advanced malignant tumors.
More
Ringene Biopharma's pan-FGFR1-4 irreversible inhibitor RG002 tablets was approved for clinical use with the help of Medicilon one-stop preclinical biopharmaceutical R&D service platform
Stock Code
688202

Global

Address: 1 Broadway, Cambridge, MA02142 (America)

Tel: +1(626)986-9880(U.S. - West Coast)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 24, Seochojungang-ro 8-gril, Seocho-gu, Seoul, 06643 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->